Clinical trials: Bladder
Overactive Bladder
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
- Trial name
- NCT00337090
- Testing
- YM178
- Where
- 84 sites in Belgium, Czechia and 13 more
- Volunteers
- 1,108 people
- Sponsor
- Astellas Pharma Inc
Cystocele, Uterine Prolapse
Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh
The purpose of this study is to determine the influence of anterior pelvic prolapse reconstruction with a titanized polypropylene mesh on patients quality of life.
- Trial name
- NCT02690220
- Testing
- TiLOOP® PRO Plus A
- Where
- 5 sites in Germany
- Volunteers
- 54 people
- Sponsor
- pfm medical gmbh
Overactive Bladder
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from…
- Trial name
- NCT01458197
- Testing
- Tarafenacin 0.2 mg, Tarafenacin 0.4 mg
- Where
- South Korea
- Volunteers
- 235 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Bladder Cancer
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.
- Trial name
- NCT03125460
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 424 people
- Sponsor
- Cepheid
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Non-small Cell Lung Cancer, Bladder Cancer
CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)
The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while sparing normal cells) and to establish a safe…
- Trial name
- STORM (NCT02043665)
- Testing
- CVA21/pembrolizumab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 85 people
- Sponsor
- Viralytics
Urinary Bladder Neoplasms
A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in Korea
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC)…
- Trial name
- BC RC DB (NCT07735793)
- Volunteers
- 1 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cancer of the Bile Duct, Gallbladder Cancer
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall…
- Trial name
- NCT00386516
- Testing
- GM-CT-01, 5-Fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Galectin Therapeutics Inc.
Urinary Disorders, Urinary Incontinence
Study Evaluating the Ability of a NIRS Module to Detect a Urodynamic Variation in Humans (DETTECH)
NIRS technology is therefore a technique that exploits the different absorption properties of oxygenated and deoxygenated hemoglobin to evaluate the degree of tissue oxygenation.
- Conditions
- Urinary Disorders, Urinary Incontinence, Urinary Bladder Diseases
- Trial name
- DETTECH (NCT04161716)
- Testing
- NIRS recording
- Where
- France
- Volunteers
- 40 people
- Sponsor
- BioSerenity
Overactive Bladder (OAB)
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
- Trial name
- NCT00507169
- Testing
- SVT-40776
- Sponsor
- Salvat
Overactive Bladder, Pharmacokinetics
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
This study investigates whether YM178 has an effect on the pharmacokinetics of warfarin, to exclude any drug-drug interaction between YM178 and warfarin, and evaluates the safety and tolerability of warfarin alone and combined…
- Trial name
- NCT00856570
- Testing
- warfarin, YM178
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Urinary Tract Infections, Pyelonephritis
A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.
The purpose of this study is to evaluate the effectiveness and safety of two antibiotics in the treatment of complicated urinary tract infection or acute pyelonephritis (kidney infection).
- Trial name
- NCT00210886
- Testing
- levofloxacin
- Volunteers
- 1,109 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overactive Bladder
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory…
- Trial name
- NCT01178827
- Testing
- trospium chloride, oxybutynin IR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Allergan
Bladder Cancer
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy…
- Trial name
- NCT02625961
- Testing
- Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation
- Volunteers
- 296 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
Cystocele
Nerve Access Tool Study
The purpose of this study is to assess the ability of the nerve access tool to facilitate nerve stimulation lead placement.
- Trial name
- NCT00942474
- Testing
- Facilitate nerve stimulation lead placement with the nerve access tool
- Sponsor
- MedtronicNeuro
Bladder Neoplasm, Neoplasm Recurrence, Local
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
This is a phase 3 randomized, active-controlled, open-label, multicenter study that will be conducted in approximately 120 investigational sites worldwide.
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ
- Trial name
- EMBARC-RF (NCT01200992)
- Testing
- EN3348, Mitomycin C
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bioniche Life Sciences Inc.
Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
- Trial name
- TAR-210 (NCT05567185)
- Testing
- Erdafitinib Intravesical Delivery System
- Where
- 4 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Janssen Pharmaceutical K.K.
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Urinary Bladder Neoplasms, Bladder Cancer
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors, Urothelial Carcinoma
- Trial name
- NCT05699135
- Testing
- Avelumab first-line maintenance
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.